Familial hypercholesterolemia (FH) \[heterozygous (heFH) or homozygous FH (hoFH)\] is a common genetic disorder, characterized by elevated plasma low density lipoprotein (LDL) cholesterol concentration leading (if untreated) to cholesterol deposits in the corneas, eyelids and extensor tendons, rapidly progressing vascular disease, and aortic valve disease.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* both genders
* \>18 years, \<80 years
* door to door enrolment
* eligible to sign informed consent
Exclusion Criteria:
* \<18 years, \>80 years
* deny to sign informed consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this Greek registry study on familial hypercholesterolaemia is already completed, would the findings from it change how you diagnose or assess my own risk for this condition?
2This trial was focused on measuring how common familial hypercholesterolaemia is in Greece — does that kind of prevalence data affect what screening or genetic testing you might recommend for me or my family members?
3Now that this registry is complete, are there any active treatment trials or newer studies for familial hypercholesterolaemia that might be more relevant to my situation right now?
4Could the data collected in this registry help inform whether my specific type of familial hypercholesterolaemia fits patterns that are particularly common or particularly serious in populations like mine?
5Given that this was an observational registry rather than a treatment study, what does it tell us — if anything — about the standard-of-care options you would recommend for managing my cholesterol levels today?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
the prevalence of Familiar Hypercholesterolaemia in Greece
Timeframe: 1 month
Trial details
NCT IDNCT03140605
SponsorHellenic College of Treatment of Atherosclerosis